Meet Proteona at J.P. Morgan: San Francisco, 7-10 Jan. 2019

Meet Proteona at the J P Morgan Conference in San Francisco Tae Fuller from Pexels

Meet the Proteona team at the 37th Annual J.P. Morgan HEALTHCARE CONFERENCE in San Francisco

Innovative genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications

Proteona announced that Dr Andreas Schmidt, Chief Executive Officer, will be at the 37th Annual J.P. Morgan HEALTHCARE CONFERENCE in San Francisco from the 7th to the 10th January, 2019.

Dr Schmidt will be available during the conference to discuss the recent development in their ESCAPE™ RNA Sequencing technology, which allows for obtaining protein and gene expression information from the same single cells.

Conference details

Schedule a meeting

For media queries, please contact:

Dr Andreas Schmidt

About Proteona

Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.